Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Corey Goodman
AddedMar 31, 2024
UpdatedJun 28, 2026
Corey Goodman

Corey Goodman

Board Member, ALX Oncology Holdings

Crunchbase

Corey Goodman's Career

ALX Oncology Holdings
ALX Oncology Holdings

South San Francisco, CA, US

Board Member· Board
Exelixis
Exelixis

Alameda, CA, US

Co-Founder
Tallac Therapeutics
Tallac Therapeutics

Burlingame, CA, US

Co-Founder
Renovis Surgical Technologies
Renovis Surgical Technologies

Redlands, CA, US

Founder
NeuroTherapeutics Pharma
NeuroTherapeutics Pharma

Chicago, IL, US

Board Member· Board
Solstice Biologics
Solstice Biologics

San Francisco, CA, US

Board Member· Board
Second Genome
Second Genome

South San Francisco, CA, US

Board Member· Board
Fog Pharmaceuticals
Fog Pharmaceuticals

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Corey Goodman's Career

ALX Oncology Holdings
ALX Oncology Holdings
Public712020South San Francisco, CA, US
Board Member· Board

Leadership at ALX Oncology Holdings

Jaume PonsJaume PonsFounder
Jack NielsenJack NielsenBoard Member
Jason LettmannJason LettmannBoard Member

Similar to ALX Oncology Holdings

OncolixOncolixHouston, TX, USCancer Treatmentest. 2007OncolixHouston, TX, US · est. 2007

Oncolix: A clinical-stage biotech firm innovating therapeutic proteins for cancer treatment.

Series A · $8.5M30
Allogene TherapeuticsAllogene TherapeuticsSouth San Francisco, CA, USCancer Therapiesest. 2017Allogene TherapeuticsSouth San Francisco, CA, US · est. 2017

San Francisco-based Allogene Therapeutics pioneers AlloCAR T™ therapies for cancer, revolutionizing allogeneic cell therapy.

Public · $781.8M361
Immune-Onc TherapeuticsImmune-Onc TherapeuticsPalo Alto, CA, USCancer Treatmentest. 2016Immune-Onc TherapeuticsPalo Alto, CA, US · est. 2016

California-based Immune-Onc Therapeutics develops therapeutic antibodies for cancer treatment.

Public · $140.1M35
OncoSpherixOncoSpherixAtlanta, GA, USCancer Treatmentsest. 2018OncoSpherixAtlanta, GA, US · est. 2018

OncoSpherix, Inc.: Advancing novel cancer treatments with proprietary therapeutics to enhance survival and quality of life.

Seed · $2.9M3
Exelixis
Exelixis
Public$514M1.2k1994Alameda, CA, US
Co-Founder

Leadership at Exelixis

George PosteGeorge PosteBoard Member
Stelios PapadopoulosStelios PapadopoulosBoard Member
Mike MorrisseyMike MorrisseyCEO
Jack L. WyszomierskiJack L. WyszomierskiBoard Member
Tallac Therapeutics
Tallac Therapeutics
Series A$88.2M342018Burlingame, CA, US
Co-Founder

Leadership at Tallac Therapeutics

Peter DudekPeter DudekBoard Member
Hong I. WanHong I. WanCo-Founder
Ayman KabakibiAyman KabakibiCo-Founder

Similar to Tallac Therapeutics

Tactiva TherapeuticsTactiva TherapeuticsBuffalo, NY, USCancer Treatmentest. 2016Tactiva TherapeuticsBuffalo, NY, US · est. 2016

Tactiva Therapeutics: Specializing in potent dual T cell receptor cancer immunotherapy.

Series A · $35M30
Torl BiotherapeuticsTorl BiotherapeuticsCulver City, CA, USCancer Therapeuticsest. 2018Torl BiotherapeuticsCulver City, CA, US · est. 2018

Culver City-based TORL-Bio, advancing novel antibody-based cancer therapeutics since 2018.

Series B · $158M18
Bolt BiotherapeuticsBolt BiotherapeuticsRedwood City, CA, USCancer Therapeuticsest. 2015Bolt BiotherapeuticsRedwood City, CA, US · est. 2015

Bolt Biotherapeutics: A biotech firm developing immune-stimulating cancer therapeutics, traded publicly in the US.

Public · $198.5M91
LTZ TherapeuticsLTZ TherapeuticsSan Francisco, CA, USImmunotherapy, Therapeuticsest. 2022LTZ TherapeuticsSan Francisco, CA, US · est. 2022

LTZ: Innovating immunotherapies for cancer and diseases with unmet clinical needs.

Seed · $27M16
Renovis Surgical Technologies
Renovis Surgical Technologies
Acquired$10.7M02011Redlands, CA, US
Founder

Similar to Renovis Surgical Technologies

RevOrthoRevOrthoGreat Neck, NY, USMedical Devicesest. 2013RevOrthoGreat Neck, NY, US · est. 2013

RevOrtho, a NY-based medical device company, innovates in orthopedic technology for enhanced implants and individualized solutions.

Angel · $50k2
OrthofixOrthofixLewisville, TX, USMedical Devicesest. 1980OrthofixLewisville, TX, US · est. 1980

Orthofix Medical Inc.: Global provider of orthopedic and spine solutions, specializing in medical devices.

Public1.1k
Renovo ConceptsRenovo ConceptsSan Antonio, TX, USMedical Devicesest. 2017Renovo ConceptsSan Antonio, TX, US · est. 2017

Texas-based Renovo Concepts manufactures innovative therapeutic tools for recovery from severe neurological injuries.

Series A · $7.3M7
Edge SurgicalEdge SurgicalChicago, IL, USMedical Devicesest. 2015Edge SurgicalChicago, IL, US · est. 2015

EDGe Surgical: Innovating precision measurement solutions for orthopedic surgery.

Pre-Seed · $5.9M12
NeuroTherapeutics Pharma
NeuroTherapeutics Pharma
Public$60.7M302006Chicago, IL, US
Board Member· Board

Leadership at NeuroTherapeutics Pharma

Stephen CollinsStephen CollinsBoard Member
Luke EvninLuke EvninBoard Member
Fran HellerFran HellerBoard Member
Dr Thomas R Beck \"Tom\"Dr Thomas R Beck \"Tom\"Board Member
Christine E SiuChristine E SiuBoard Member
Elaine V. JonesElaine V. JonesBoard Member
Solstice Biologics
Solstice Biologics
Series C$47.5M302012San Francisco, CA, US
Board Member· Board

Leadership at Solstice Biologics

Lou TartagliaLou TartagliaBoard Member
Robert AdelmanRobert AdelmanBoard Member
Curt BradshawCurt BradshawFounder

Similar to Solstice Biologics

NucleonicsNucleonicsHorsham, PA, USBiomedical Products, Therapeuticsest. 2001NucleonicsHorsham, PA, US · est. 2001

Global provider of innovative biomedical products, specializing in RNA interference therapeutics.

Series B · $51.4M30
LocanabioLocanabioSan Diego, CA, USGene Therapiesest. 2016LocanabioSan Diego, CA, US · est. 2016

Locana: Pioneering RNA-targeting gene therapies for devastating diseases.

Series B · $155.6M175
SirnaomicsSirnaomicsGaithersburg, MD, USTherapeuticsest. 2007SirnaomicsGaithersburg, MD, US · est. 2007

US-based Sirnaomics, Inc. is a biopharmaceutical firm specializing in ocular neovascularization therapeutics.

Public · $275M30
Silvec BiologicsSilvec BiologicsGaithersburg, MD, USRNA Therapiesest. 2019Silvec BiologicsGaithersburg, MD, US · est. 2019

Silvec Biologics offers RNA therapies for tree diseases, preserving food supplies and ecosystems.

Angel · $406k11
Second Genome
Second Genome
Acquired$62.5M02009South San Francisco, CA, US
Board Member· Board

Leadership at Second Genome

Brad MargusBrad MargusBoard Member
Jill CarrollJill CarrollBoard Member
Janet WarringtonJanet WarringtonCo-Founder
Todd DeSantisTodd DeSantisCo-Founder
Karim DabbaghKarim DabbaghBoard Member
Mike CarusiMike CarusiBoard Member
Fog Pharmaceuticals
Fog Pharmaceuticals
Series D$385.3M1472015Cambridge, MA, US
Board Member· Board

Leadership at Fog Pharmaceuticals

Barbara WeberBarbara WeberBoard Member
Rick KlausnerRick KlausnerBoard Member
Gregory L. VerdineGregory L. VerdineCo-Founder
Weiqing ZhouWeiqing ZhouCo-Founder
Edward FitzgeraldEdward FitzgeraldBoard Member
Jeffrey LeerinkJeffrey LeerinkBoard Member

Similar to Fog Pharmaceuticals

Foghorn TherapeuticsFoghorn TherapeuticsCambridge, MA, USDrug Development, Pharmaceuticalsest. 2015Foghorn TherapeuticsCambridge, MA, US · est. 2015

Foghorn Therapeutics Inc., a US-based pharmaceutical company, innovates novel drugs for cancer and serious disorders.

Public · $111M161
Camino PharmaCamino PharmaSan Diego, CA, USCancer Treatment, Drug Developmentest. 2014Camino PharmaSan Diego, CA, US · est. 2014

Camino Pharma: A tech startup pioneering first-in-class cancer and CNS disorder therapies.

Seed · $13.7M3
Tigris PharmaceuticalsTigris PharmaceuticalsBonita Springs, FL, USCancer Treatmentsest. 2005Tigris PharmaceuticalsBonita Springs, FL, US · est. 2005

Tigris Pharmaceuticals: Innovating biopharmaceutical solutions for cancer and other medical needs.

Series C · $32.5M6
Frontier MedicinesFrontier MedicinesSouth San Francisco, CA, USPrecision Medicine, Therapeuticsest. 2018Frontier MedicinesSouth San Francisco, CA, US · est. 2018

Frontier Medicines, a US-based precision medicine firm, pioneers in developing treatments for previously undruggable diseases.

Series B · $244M128

Corey Goodman's Co-Investors

Franklin BergerFranklin BergerCo-invested · MindRhythm SeedKyle YorkKyle YorkCo-invested · MindRhythm SeedDavid LamondDavid LamondCo-invested · MindRhythm SeedPierre LamondPierre LamondCo-invested · MindRhythm SeedShayna ModarresiShayna ModarresiCo-invested · Queenly Pre-SeedRobert HessRobert HessCo-invested · Queenly Pre-SeedThuan PhamThuan PhamCo-invested · Queenly Pre-SeedJason WangJason WangCo-invested · Queenly Pre-Seed

Corey Goodman's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Corey Goodman

Keith FlahertyKeith FlahertyBoard Member · X4 PharmaceuticalsScott J. DyllaScott J. DyllaBoard Member · Chimera BioengineeringNick NaclerioNick NaclerioFounder · Illumina VenturesCraig C TaylorCraig C TaylorCo-Founder · Alloy VenturesBuzz BensonBuzz BensonFounder · Piper JaffrayDan BradburyDan BradburyFounder · Biobrit